Hypertrophy of the heart: a new therapeutic target?

By N. Frey, H. Katus, E. Olson, Joseph A. Hill. Circulation, 2004

869 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy (2005, background): “This response involves the stimulation of multiple signaling and transcription pathways that induce hypertrophic remodelin”
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. (2009, background): “org Volume 119 Number 9 September 2009 2773 mon feature of cardiac hypertrophy and heart failure in both mouse and human hearts (19, 20).”
Pathological Ventricular Remodeling: Mechanisms: Part 1 of 2 (2013, background): “If true, suppressing pathological hypertrophy may be key to impeding the progression to heart failure.(32)”
Cardiac autophagy is a maladaptive response to hemodynamic stress. (2007, background): “Numerous signaling pathways have been causally implicated in stress-induced remodeling of the heart (2, 3), and many of these same pathways have also been implicated in cell death.”
Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. (2009, background): “In recent years, much progress has been made in our understanding of hypertrophic activators (1); however, relatively little is known about endogenous negative regulators of cardiac growth, which have potential to block the cardiac hypertrophic response (reviewed in ref.”